Sign Out
Pregnancy: Irinotecan may cause fetal harm when administered to a pregnant woman. If the drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Irinotecan.
Lactation: Because many drugs are excreted in human milk, and because of the potential for adverse reactions in nursing infants, breast-feeding must be discontinued for the duration of Irinotecan therapy.
